Home › NCT06836141

Biomarkers for Cognitive Decline in Intracerebral Hemorrhage

Silent Brain Infarcts in Spontaneous Intracerebral Hemorrhage as a Prognostic Biomarker for Vascular Contributions to Cognitive Impairment and Dementia (VCID)

Who can join

Ages 18 to 80 · All sexes

Inclusion Criteria:

* Primary Intracerebral Hemorrhage
* Age ≥ 18 and \< 80 years

Exclusion Criteria:

* Pre-existing dementia

About the study

The goal of this clinical trial is to see if silent brain infarcts (SBIs), or stroke-like symptoms detectable during brain imaging, are a possible contributor to cognitive decline for patients diagnosed with spontaneous intracerebral hemorrhage (sICH), or blood clot in the brain. The main questions it aims to answer are

* if SBIs in sICH are associated with a lower cognitive level and more rapid cognitive decline * if SBIs in sICH are associated with certain findings on brain imaging * if SBIs in sICH are associated with higher inflammation measured by certain blood tests

Participants will undergo

* cognitive testing during hospitalization, and at 3, 6 and 12 months after the sICH * Magnetic Resonance Imaging (MRI) of the brain during hospitalization and 12 months after the sICH * blood draws during hospitalization and at 3, 6 and 12 months after the sICH

What is being tested

• MRI (diagnostic test)
• Blood Draw (diagnostic test)
• Cognitive Test (diagnostic test)

Sponsor: Rush University Medical Center · Participants: 118 · Started: Aug 2, 2025

Contact the study team

• Amanda Sremac, BS · Phone: 312-942-0593

Official record on ClinicalTrials.gov — NCT06836141

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.